August 24, 2026 10:24 am (IST)
Follow us:
Strides Arcolab signs agreement with Gilead Sciences
Bangalore/Kolkata, Jan 20 (IBNS): Strides Arcolab Limited (Strides) on Tuesday announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.
The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.
As part of the licensing agreement, pending U.S. Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.
TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead’s Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Yes Bank launches ‘YES Essence’ for women. How can you avail it?
Fri, Aug 21 2026
Aditya Birla Capital enters gold loans: What consumers should know
Fri, Aug 21 2026
Citibank N.A. India’s client asset book crosses ₹1 lakh crore despite consumer banking divestiture
Fri, Aug 21 2026
Cellecor becomes first Indian consumer electronics brand to manufacture in Africa. All details here
Fri, Aug 21 2026
Trump’s ‘economic D-Day’ warning to Iran rattles markets: Sensex, Nifty turn volatile
Fri, Aug 21 2026